A study testing whether a GLP-1 medicine from Lilly, orforglipron, can lower blood sugar and help with weight.
- Who can join
- Children and teens 10 to 17, have type 2 diabetes.
- What you take
- orforglipron, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The full study runs about 3.5 years; your own time in it is usually shorter.
- What you get
- The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
What this study is for
Primary condition: Diabetes Mellitus, Type 2.
For trial evidence and insurance approval criteria for this condition, see the Type 2 diabetes condition guide.
Full scientific study title: A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes.
Who can join
Children and teens 10 to 17, have type 2 diabetes. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Have type 2 diabetes treated with diet and exercise and metformin and/or basal insulin
- Have HbA1c > 6.5% to <= 11.0% at screening
- Have a body weight >=50 kilograms (kg) (110 pounds) and a body mass index (BMI) of >85th percentile
Key exclusion criteria
- Have type 1 diabetes
- After the type 2 diabetes diagnosis, have a history of diabetic ketoacidosis or hyperosmolar syndrome
- Have had at least one episode of severe hypoglycemia and/or at least one episode of hypoglycemic unawareness within the last 6 months before screening
- Have a history of pancreatitis or gallbladder disease
- Have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2)
Where this study is enrolling
This trial has 17 sites across 10 states. Contact a site coordinator directly to start screening.
California2 sites
- Sutter Valley Medical Foundation (SVMF) Pediatric EndocrinologySacramento, California916-426-1902
- Rady Children's HospitalSan Diego, California858-966-8940
Connecticut1 site
- Stamford Therapeutics ConsortiumStamford, Connecticut
Georgia2 sites
- Children's Healthcare of Atlanta - Center for Advanced Pediatrics (CAP)Atlanta, Georgia
- CenExel iResearch, LLCDecatur, Georgia404-537-1281
Idaho1 site
- Medical Research PartnersAmmon, Idaho208-522-4600
Kansas1 site
- Cotton O'Neil Diabetes & EndocrinologyTopeka, Kansas785-354-9591
New York2 sites
- SUNY Upstate Medical UniversitySyracuse, New York
- Advantage Clinical TrialsThe Bronx, New York917-962-0234
Oklahoma1 site
- Central States ResearchTulsa, Oklahoma918-645-5400
Pennsylvania1 site
- Frontier Clinical Research, LLCSmithfield, Pennsylvania724-569-8036
Tennessee1 site
- Vanderbilt Health One Hundred OaksNashville, Tennessee225-226-5662
Texas5 sites
- Gadolin ResearchBeaumont, Texas409-331-6040
- Driscoll Children's HospitalCorpus Christi, Texas361-739-7250
- Proactive Clinical Research LLCEdinburg, Texas956-731-1260
- Consano Clinical Research, LLCShavano Park, Texas210-545-4900
- Victoria Clinical Research GroupVictoria, Texas361-210-7869
Timeline
Started enrolling: 2026-09. Expected completion: 2030-03. Last updated on ClinicalTrials.gov: 2026-06-25.
Official source
We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
